Kura Oncology (KURA) Assets (2010 - 2026)
Kura Oncology (KURA) posted quarterly Assets of $652.6 million for Q1 2026, down 12.26% year-over-year from $743.8 million in Q1 2025, and down 11.62% quarter-over-quarter from $738.4 million in Q4 2025.
Kura Oncology (KURA) Assets (2010 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Assets for 17 consecutive years, with $652.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets fell 12.26% year-over-year to $652.6 million; the TTM figure through Mar 2026 stood at $652.6 million (down 12.26% YoY), while the FY2025 annual figure was $738.4 million, down 2.87% from the prior year.
- Assets eased to $652.6 million in Q1 2026 per KURA's latest filing, from $738.4 million in the prior quarter.
- Across five years, Assets topped out at $760.2 million in Q4 2024 and bottomed at $426.0 million in Q1 2023.
- Historically, Assets has averaged $558.4 million across 5 years, with a median of $498.6 million in 2022.
- Annual changes were most pronounced in 2022 — Assets declined 20.16% — and 2024, when it soared 69.32%.
- Kura Oncology's Assets stood at $456.3 million in 2022, then declined by 1.62% to $448.9 million in 2023, then soared by 69.32% to $760.2 million in 2024, then fell by 2.87% to $738.4 million in 2025, then declined by 11.62% to $652.6 million in 2026.
- Business Quant data shows KURA's Assets at $652.6 million in Q1 2026, $738.4 million in Q4 2025, and $649.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | 587.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 587.79 Mn |
| Mar 31, 2026 | 652.55 Mn |
| Dec 31, 2025 | 738.36 Mn |
| Sep 30, 2025 | 649.38 Mn |
| Jun 30, 2025 | 682.43 Mn |
| Mar 31, 2025 | 743.76 Mn |
| Dec 31, 2024 | 760.16 Mn |
| Sep 30, 2024 | 478.84 Mn |
| Jun 30, 2024 | 515.12 Mn |
| Mar 31, 2024 | 553.91 Mn |
| Dec 31, 2023 | 448.94 Mn |
| Sep 30, 2023 | 473.77 Mn |
| Jun 30, 2023 | 494.74 Mn |
| Mar 31, 2023 | 425.98 Mn |
| Dec 31, 2022 | 456.31 Mn |
| Sep 30, 2022 | 447.99 Mn |
| Jun 30, 2022 | 471.43 Mn |
| Mar 31, 2022 | 498.59 Mn |
| Dec 31, 2021 | 534.05 Mn |
| Sep 30, 2021 | 561.14 Mn |